{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:56:45Z","timestamp":1768589805042,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10157-025-02766-w","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:41:11Z","timestamp":1758195671000},"page":"75-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of dapagliflozin on uric acid in patients with moderate-to-severe chronic kidney disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Katsunori","family":"Yanai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-2478","authenticated-orcid":false,"given":"Keiji","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taisuke","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhisa","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyonori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Ookawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"10296","key":"2766_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(21)00536-5.","journal-title":"Lancet"},{"issue":"1","key":"2766_CR2","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26\u201339. https:\/\/doi.org\/10.1016\/j.kint.2017.12.027.","journal-title":"Kidney Int"},{"issue":"2","key":"2766_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.09380822","volume":"18","author":"BF Palmer","year":"2023","unstructured":"Palmer BF, Clegg DJ. Kidney-protective effects of SGLT2 inhibitors. Clin J Am Soc Nephrol. 2023;18(2):279\u201389.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"2766_CR4","doi-asserted-by":"publisher","first-page":"e230005","DOI":"10.1530\/EC-23-0005","volume":"12","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12(8):e230005.","journal-title":"Endocr Connect"},{"key":"2766_CR5","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1828-23","author":"D Mori","year":"2023","unstructured":"Mori D, Kobayashi M, Wada M, Tokuchi M, Misegawa S, Saito R, et al. Effect of dapagliflozin on serum uric acid levels in patients with advanced chronic kidney disease. Intern Med. 2023. https:\/\/doi.org\/10.2169\/internalmedicine.1828-23.","journal-title":"Intern Med"},{"issue":"15","key":"2766_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"2766_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"Group E-KC","year":"2023","unstructured":"Group E-KC. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"11","key":"2766_CR8","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1681\/ASN.2022030306","volume":"33","author":"N Jongs","year":"2022","unstructured":"Jongs N, Chertow GM, Greene T, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Correlates and consequences of an acute change in eGFR in response to the SGLT2 inhibitor dapagliflozin in patients with CKD. J Am Soc Nephrol. 2022;33(11):2094\u2013107. https:\/\/doi.org\/10.1681\/ASN.2022030306.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2766_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/dom.13670","volume":"21","author":"CJ Bailey","year":"2019","unstructured":"Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291\u20138. https:\/\/doi.org\/10.1111\/dom.13670.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2766_CR10","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1038\/s41598-023-32072-y","volume":"13","author":"Y Iwata","year":"2023","unstructured":"Iwata Y, Notsu S, Kawamura Y, Mitani W, Tamai S, Morimoto M, et al. The effect of dapagliflozin on uric acid excretion and serum uric acid level in advanced CKD. Sci Rep. 2023;13(1):4849. https:\/\/doi.org\/10.1038\/s41598-023-32072-y.","journal-title":"Sci Rep"},{"issue":"6","key":"2766_CR11","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53(6):982\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2008.12.034.","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"2766_CR12","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/dia.2018.0169","volume":"20","author":"T Osonoi","year":"2018","unstructured":"Osonoi T, Gouda M, Kubo M, Arakawa K, Hashimoto T, Abe M. Effect of canagliflozin on urinary albumin excretion in Japanese patients with type 2 diabetes mellitus and microalbuminuria: a pilot study. Diabetes Technol Ther. 2018;20(10):681\u20138. https:\/\/doi.org\/10.1089\/dia.2018.0169.","journal-title":"Diabetes Technol Ther"},{"issue":"12","key":"2766_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/dia.2019.0212","volume":"21","author":"T Maruyama","year":"2019","unstructured":"Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther. 2019;21(12):713\u201320. https:\/\/doi.org\/10.1089\/dia.2019.0212.","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"2766_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10157-018-1648-1","volume":"23","author":"Japanese Society of N","year":"2019","unstructured":"Japanese Society of N. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin Exp Nephrol. 2019;23(1):1\u201315. https:\/\/doi.org\/10.1007\/s10157-018-1648-1.","journal-title":"Clin Exp Nephrol"},{"key":"2766_CR15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2147\/DMSO.S399343","volume":"16","author":"M Dong","year":"2023","unstructured":"Dong M, Chen H, Wen S, Yuan Y, Yang L, Xu D, et al. The mechanism of sodium-glucose cotransporter-2 inhibitors in reducing uric acid in type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2023;16:437\u201345. https:\/\/doi.org\/10.2147\/DMSO.S399343.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"7","key":"2766_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/jcdd10070268","volume":"10","author":"A Kochanowska","year":"2023","unstructured":"Kochanowska A, Rusztyn P, Szczerkowska K, Surma S, Gasecka A, Jaguszewski MJ, et al. Sodium-glucose cotransporter 2 inhibitors to decrease the uric acid concentration-a novel mechanism of action. J Cardiovasc Dev Dis. 2023;10(7):268. https:\/\/doi.org\/10.3390\/jcdd10070268.","journal-title":"J Cardiovasc Dev Dis"},{"key":"2766_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-020-01953-z","volume":"21","author":"H Guan","year":"2020","unstructured":"Guan H, Zheng Y, Zhou X, Xu Y, Fu C, Xiao J, et al. Efficacy of different urinary uric acid indicators in patients with chronic kidney disease. BMC Nephrol. 2020;21:1\u20139.","journal-title":"BMC Nephrol"},{"issue":"1","key":"2766_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12882-018-0892-7","volume":"19","author":"F Li","year":"2018","unstructured":"Li F, Guo H, Zou J, Chen W, Lu Y, Zhang X, et al. Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study. BMC Nephrol. 2018;19(1):95. https:\/\/doi.org\/10.1186\/s12882-018-0892-7.","journal-title":"BMC Nephrol"},{"key":"2766_CR19","doi-asserted-by":"publisher","first-page":"945","DOI":"10.2147\/IJGM.S277957","volume":"13","author":"K Kritmetapak","year":"2020","unstructured":"Kritmetapak K, Charoensri S, Thaopanya R, Pongchaiyakul C. Elevated serum uric acid is associated with rapid decline in kidney function: a 10-year follow-up study. Int J Gen Med. 2020;13:945\u201353. https:\/\/doi.org\/10.2147\/IJGM.S277957.","journal-title":"Int J Gen Med"},{"issue":"11","key":"2766_CR20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):755\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2766_CR21","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1373\/clinchem.2009.124891","volume":"55","author":"W Zhang","year":"2009","unstructured":"Zhang W, Sun K, Yang Y, Zhang H, Hu FB, Hui R. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem. 2009;55(11):2026\u201334. https:\/\/doi.org\/10.1373\/clinchem.2009.124891.","journal-title":"Clin Chem"},{"issue":"6","key":"2766_CR22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/01.hyp.36.6.1072","volume":"36","author":"P Verdecchia","year":"2000","unstructured":"Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. the PIUMA study. Hypertension. 2000;36(6):1072\u20138. https:\/\/doi.org\/10.1161\/01.hyp.36.6.1072.","journal-title":"Hypertension"},{"issue":"5","key":"2766_CR23","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","volume":"60","author":"B Soletsky","year":"2012","unstructured":"Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012;60(5):1148\u201356. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.196980.","journal-title":"Hypertension"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02766-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02766-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:38:23Z","timestamp":1768545503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02766-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02766-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of Ethics Committee of Jichi Medical University at which the studies were conducted (IRB approval number: S23-148) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was waived because of the study\u2019s retrospective nature. Information regarding this study, including the patients\u2019 right to opt out, has been uploaded to the website of the Medical Center\u2019s waiting areas.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}